CLDX · Insider Trading
Celldex Therapeutics, Inc
Every open-market purchase and sale reported by CLDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Rita Jain | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Ronald Pepin | SR. VP & CBO | A | +20,000 deriv. | — |
| 2026-06-29 | Harry Penner Jr | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Samuel Bates Martin | SVP AND CFO | A | +93,000 deriv. | — |
| 2026-06-29 | Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | A | +95,000 deriv. | — |
| 2026-06-29 | Keith L Brownlie | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Garry Arthur Neil | Director | A | +26,000 deriv. | — |
| 2026-06-29 | James J Marino | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Herbert J Conrad | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | A | +95,000 deriv. | — |
| 2026-06-29 | Tibor Keler | EXECUTIVE VP & CSO | A | +115,000 deriv. | — |
| 2026-06-29 | Teri L Lawver | SVP & Chief Commercial Officer | A | +90,000 deriv. | — |
| 2026-06-29 | Denice Torres | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Anthony S Marucci | PRESIDENT & CEO | A | +375,000 deriv. | — |
| 2026-06-29 | Freddy A. Jimenez | SVP & GENERAL COUNSEL | A | +93,000 deriv. | — |
| 2026-06-29 | Cheryl Cohen | Director | A | +26,000 deriv. | — |
| 2026-06-29 | Diane C. Young | SVP, CHIEF MEDICAL OFFICER | A | +57,000 deriv. | — |
| 2026-06-29 | Elizabeth Crowley | SR. VP & CPDO | A | +100,000 deriv. | — |
| 2026-01-06 | Samuel Bates Martin | SVP AND CFO | M | +4,817 | +$50.00K |
| 2025-12-17 | Ronald Pepin | SR. VP & CBO | M | +19,333 | +$105.71K |
| 2025-12-08 | Freddy A. Jimenez | SVP & GENERAL COUNSEL | Sell | −4,166 | −$121.21K |
| 2025-11-17 | Richard M. Wright | — | MIXED | — | −$490.26K |
| 2025-11-12 | Teri L Lawver | SVP & Chief Commercial Officer | A | +100,000 deriv. | — |
| 2025-08-15 | Freddy A. Jimenez | SVP & GENERAL COUNSEL | Sell | −771 | −$19.10K |
| 2025-06-09 | Samuel Bates Martin | SVP AND CFO | A | +81,000 deriv. | — |
| 2025-06-09 | Cheryl Cohen | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Herbert J Conrad | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Ronald Pepin | SR. VP & CBO | A | +20,000 deriv. | — |
| 2025-06-09 | Freddy A. Jimenez | SVP & GENERAL COUNSEL | A | +75,000 deriv. | — |
| 2025-06-09 | Tibor Keler | EXECUTIVE VP & CSO | A | +93,000 deriv. | — |
| 2025-06-09 | Harry Penner Jr | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Anthony S Marucci | PRESIDENT & CEO | A | +300,000 deriv. | — |
| 2025-06-09 | Garry Arthur Neil | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | A | +78,000 deriv. | — |
| 2025-06-09 | Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | A | +82,000 deriv. | — |
| 2025-06-09 | Diane C. Young | SVP, CHIEF MEDICAL OFFICER | A | +72,000 deriv. | — |
| 2025-06-09 | Rita Jain | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Keith L Brownlie | Director | A | +16,500 deriv. | — |
| 2025-06-09 | Denice Torres | Director | A | +33,000 deriv. | — |
| 2025-06-09 | Elizabeth Crowley | SR. VP & CPDO | A | +85,000 deriv. | — |
| 2025-06-09 | James J Marino | Director | A | +16,500 deriv. | — |
| 2024-11-20 | James J Marino | Director | G | −10,500 | — |
| 2024-11-12 | Anthony S Marucci | PRESIDENT & CEO | Buy | +11,500 | +$308.43K |
| 2024-06-18 | Samuel Bates Martin | SVP AND CFO | MIXED | +2,997 | −$403.33K |
| 2024-06-18 | Elizabeth Crowley | SR. VP & CPDO | MIXED | — | −$734.56K |
| 2024-06-17 | Karen L. Shoos | Director | A | +16,500 deriv. | — |
| 2024-06-17 | Harry Penner Jr | Director | A | +16,500 deriv. | — |
| 2024-06-17 | James J Marino | Director | A | +16,500 deriv. | — |
| 2024-06-17 | Cheryl Cohen | Director | A | +16,500 deriv. | — |
| 2024-06-17 | Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | A | +78,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Anthony S Marucci | PRESIDENT & CEO | 40,284 | $1.20M |
| Elizabeth Crowley | SR. VP & CPDO | 39,074 | $1.16M |
| Samuel Bates Martin | SVP AND CFO | 32,942 | $977.39K |
| Freddy A. Jimenez | SVP & GENERAL COUNSEL | 30,796 | $913.72K |
| Richard M. Wright | SR. VP & CCO | 27,709 | $822.13K |
| Diane C. Young | SVP, CHIEF MEDICAL OFFICER | 17,115 | $507.80K |
| Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | 13,383 | $397.07K |
| Ronald Pepin | SR. VP & CBO | 9,097 | $269.91K |
| Tibor Keler | EXECUTIVE VP & CSO | 7,357 | $218.28K |
| James J Marino | Director | 2,204 | $65.39K |
| Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | 1,860 | $55.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.